Chen C J, Herring J, Chen A S
University of Mississippi Medical Center, Department of Ophthalmology, Jackson 39216, USA.
J Miss State Med Assoc. 1995 Jul;36(7):201-8.
Diabetic retinopathy (DR), an ocular complication of diabetes mellitus, is the leading cause of blindness in Americans age 20 to 74 today. The more severe stage of the disease, proliferative diabetic retinopathy, affects an estimated 700,000 Americans. Based on clinical findings, the disease is generally classified as nonproliferative DR or proliferative DR. While the former often begins as a symptomatically silent disease, it nevertheless may be progressing to itself cause significant visual loss. Based principally on evidence from several studies sponsored by the National Eye Institute, current treatment consists of regular observation by an ophthalmologist, laser photocoagulation, and vitrectomy. In addition, preventive methods such as tight glycemic control and ophthalmic screening of diabetics appear beneficial. While the ophthalmologist can provide specialized services for the DR patient, prevention and control lie largely in the hands of the primary care physician. Thus, only when primary and specialized care have established a strong partnership can they save the sight of the thousands at risk for diabetic retinopathy.
糖尿病性视网膜病变(DR)是糖尿病的一种眼部并发症,是当今美国20至74岁人群失明的主要原因。该疾病的更严重阶段,即增殖性糖尿病性视网膜病变,估计影响70万美国人。根据临床发现,该疾病通常分为非增殖性DR或增殖性DR。虽然前者通常一开始是无症状的疾病,但它仍可能进展至导致严重的视力丧失。目前的治疗主要基于国立眼科研究所赞助的多项研究的证据,包括由眼科医生定期观察、激光光凝治疗和玻璃体切除术。此外,诸如严格控制血糖和对糖尿病患者进行眼科筛查等预防方法似乎有益。虽然眼科医生可以为DR患者提供专业服务,但预防和控制很大程度上掌握在初级保健医生手中。因此,只有当初级保健和专科护理建立起强有力的合作关系时,他们才能挽救成千上万有糖尿病性视网膜病变风险人群的视力。